Doxycycline;La doxycycline

Medecine Tropicale

Volumn 69, Issue 6, 2009, Pages 556-558

  Aupee, O ^a   Almeras, D ^a   Le Garlantezec, P ^a   Bohand, X ^b  

^a University of Paris Descartes   (France)

^b PERCY MILITARY HOSPITAL   (France)

Author keywords

Doxycycline; Indications; Pharmacology

Indexed keywords

DOXYCYCLINE; ANTIINFECTIVE AGENT;

ACNE CONGLOBATA; ANTHRAX; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIOSTASIS; BORRELIA INFECTION; BRUCELLOSIS; CHLAMYDIASIS; CHOLERA; DIARRHEA; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LACTATION; LEPTOSPIROSIS; LUNG INFECTION; MALARIA; MYCOPLASMOSIS; NAUSEA; NONHUMAN; PASTEURELLOSIS; PLASMODIUM; PREGNANCY; Q FEVER; RICKETS; ROSACEA; STOMACH DISCOMFORT; TREPANOMATOSIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; CHEMICAL STRUCTURE; HALF LIFE TIME;

ANTI-BACTERIAL AGENTS; DOXYCYCLINE; HALF-LIFE; HUMANS; MOLECULAR STRUCTURE;

EID: 77649203006     PISSN: 0025682X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Fabre J, Milek E, Kalfopoulos P, Mérier G. La cinétique des tétracyclines chez l'homme : absorption digestive et concentrations sériques. Schweiz Med Wochenschr 1971; 101 : 593-8.
2. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15 : 355-66. (Pubitemid 19012674)
3. Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit 1982; 4 : 115-35. (Pubitemid 12073128)
4. Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 1977; 11 : 462-9. (Pubitemid 8065607)
5. Meyer FP, Specht H, Quednow B, Walther H. Influence of milk on the bioavailability of doxycycline - new aspects. Infection 1989; 17 : 245-6.
6. Deppermann KM, Lode H, Höffken G, Tschink G, Kalz C, Koepe P. Influence of ranitidine, pirenzepine, and aluminium magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1989; 33 : 1901-7. (Pubitemid 19266252)
7. Nelis HJ, DeLeenheer AP. Liquid chromatographic estimation of doxycycline in human tissues. Clin Chim Acta 1980; 103 : 209-17. (Pubitemid 10138831)
8. Maibach H. Second-generation tetracyclines, a dermatologic overview : clinical uses and pharmacology. Curtis 1991; 48 : 411-7.
9. Blum JJ, Yayon A, Friedman S, Ginsburgh H. Effects of mitochondrial protein synthesis inhibitors on the incorporation of isoleucine into Plasmodium falciparum in vitro. J Protozool 1984; 31 : 475-9. (Pubitemid 14020766)
10. Kiatfuengfoo R, Suthiphongchai T, Prapunwattana P, Yuthavong Y. Mitochondria as the site of action of tetracycline on Plasmodium falciparum. Mol Biochem Parasitol 1989; 34 : 109-15. (Pubitemid 19098376)
11. Budimulja AS, Syafruddin, Tapchaisri P, Wilairat P, Marzuki S. The sensitivity of Plasmodium protein synthesis to prokaryotic ribosomal inhibitors. Mol Biochem Parasitol 1997; 84 : 137-41. (Pubitemid 27090514)
12. Prapunwattana P, O'Sullivan WJ, Yuthavong Y. Depression of Plasmodium falciparum dihydroorotate dehydrogenase activity in vitro culture by tetracycline. Mol Biochem Parasitol 1988; 27 : 119-24. (Pubitemid 18020214)
13. Humbert P, Treffel P, Chapuis JF, Buchet S, Derancourt C, Agache P. The tetracyclines in dermatology. J Am Acad Dermatol 1991; 25 : 691-7.
14. Société française de dermatologie. Traitements de l'acné par voie générale : indications et problèmes posés. Ann Dermatol Venereol 1995; 122 : 30-6.
15. Maurin M, Brion JP. Brucellose. EMC, Maladies Infectieuses, 2009 ; 8-038-A-10.
16. Götkas P. Comparison of streptomycin-tetracycline versus streptomycin-doxycycline in the treatment of brucellosis : the relationship between delay in therapy and its becoming chronic. Curr Ther Res 1992; 51 : 553-61.
17. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS et al. The clinical assessment, treatment and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis : clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43 : 1089-134. (Pubitemid 44637131)
18. Smith M, Gettinby G, Granström M, Gray JS, Guy EC, Revie C et al. The European Union Concerted Action World Wide Web site for Lyme borreliosis. Zentralbl Bakteriol 1998; 287 : 266-9. (Pubitemid 28202526)
19. Hansmann Y. Le traitement des phases secondaires et tertiaires de la borréliose de Lyme. Med Mal Infect 2007; 37 : 479-86.
20. Nadelman RB, Nowarowski J, Fish D, Falco RC, Freeman K, McKenna D et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345 : 79-84. (Pubitemid 32634565)
21. Hansmann Y. Rickettsioses éruptives. EMC Maladies Infectieuses 2009 ; 8-037-I-20.
22. Berbis P. Rickettsioses. EMC Dermatologie 2007 ; 98-341-A-10.
23. Lagier JC, Doudier B, Parola P. Rickettsioses. EMC Traité de Médecine Akos 2009; 4-1110.
24. Houpikian P, Perolat P, Baranton G, Brouqui P. Leptospiroses. EMC Maladies Infectieuses 2002 ; 8-039-G-10.
25. Dutta D, Bhattacharya SK, Bhattacharya MK, Deb A, Deb M, Manna B. Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae O139 infection. J Antimicrob Chemother 1996; 37 : 557-81.
26. Guevart E, Solle J, Mouangue A, Noeske J, Bita A, Fonkoua MC, et al. Evolution de la sensibilité de Vibrio cholerae 01 après utilisation prolongée d'antibiotiques en traitement et en prophylaxie au cours de l'épidémie de choléra de Douala (Cameroun) 2004. Med Mal Infect 2006; 36 : 329-34.
27. Million M, Lepidi H, Raoult D. Fièvre Q : actualités diagnostiques et thérapeutiques. Med Mal Infect 2009; 39 : 82-94.
28. Bonnetblanc JM. Doxycycline. Ann Dermatol Venereol 2002; 129 : 874-82.
29. Roig J, Casal J, Gispert P, Gea E. Antibiothérapie des pneumonies aiguës communautaires (CAP) dues à des agents atypiques. Med Mal Infect 2006; 36 : 680-9.
30. Briolant S, Almeras L, Fusai T, Rogier C, Pradines B. Cyclines et paludisme. Med Trop 2007; 67 : 86-96. (Pubitemid 350157239)
31. Caraco Y, Rubinow A. Enhanced anticoagulant effect of coumarin derivatives induced by doxycycline coadministration. Ann Pharmacother 1992; 26 : 1084-6.
32. Carlborg B, Farmer J. Esophageal corrosion tests with doxycycline monohydrate tablets. Curr Ther Res 1983; 34 : 110-5.
33. Lanza FL. Esophageal ulceration produced by doxycycline : review of the literature and comprison of the injury from doxycycline hyclate and hydrochloride with that from doxycycline monohydrate. Curr Ther Res 1988; 44 : 475-84.
34. Loesche C, Bocquet JL, Bonnevalle A, Fertin V, Thomas P. Etude de la phototoxicité chez 30 sujets traités par la doxycycline à différentes doses. Nouv Dermatol 1994; 13 : 383-8.
35. Rabar D, Combemale P, Peyron F. Doxycycline-induced photo-onycholysis. J Travel Med 2004; 11 : 386-7. (Pubitemid 39627096)
36. Correia O, Delgado L, Polónia J. Genital fixed drug eruption : cross-reactivity between doxycycline and minocycline. Clin Exp Dermatol 1999; 24 : 137. (Pubitemid 29223026)
37. Tsankov N, Antonov D, Grozdev I. Doxycycline : réponse à Jean-Marie Bonnetblanc. Ann Dermatol Venereol 2003; 130 : 789